Miracell Launches Special Service for Overseas Medical Consumers Traveling for Immune Stem Cell Treatment
[Financial News 2020.02.26] [Edaily Reporter Lee Soon-yong] As the novel coronavirus (COVID-19) pandemic continues, interest in boosting immunity as a means of preventing infection is growing more than ever. Amidst this, a program offering “Immune Stem Cell IV Injections and Immune Cell Maintenance” is attracting attention, offering both injection and storage services to prevent infection risks. The company behind this highly anticipated program is Miracell Co., Ltd. (CEO Shin Hyun-soon). Miracell has received approval from the Ministry of Food and Drug Safety and the Ministry of Health and Welfare for a specialized technology that extracts, separates, and concentrates blood or bone marrow stem cells. While some people previously spent significant amounts of money traveling to China and Japan to receive stem cell and immune cell injections, the global emergency caused by COVID-19 has now forced air travel to be halted for the first time in recorded history. Considering this situation, Miracell has established a special financial program to provide emergency support for immune stem cell IV injections and immune cell maintenance and storage. This program, called Miracell 240, has significantly relaxed payment terms to make it more accessible to consumers. CEO Shin Hyun-soon explained, “We’ve developed a convenient program for emergency immune stem cell IV injections and immune cell maintenance through agreements with financial institutions.” This program utilizes safe autologous stem cells and immune cells directly through minimal manipulation. It injects total cells, including growth cells, platelets, various immune cells, and hematopoietic stem cells, ensuring the freshest cells are injected directly in the required dose. Specifically, immune status is checked through an NK cell activity test prior to injection, and then repeated approximately 10 days later to ensure a consistent immune response. CEO Shin emphasized, “There are many questions about side effects, but because we use autologous cells, the risk of side effects is very low.” Experts in preventive medicine explain that maintaining good health while in good health can lead to a long and healthy life. Going forward, the global medical market will likely focus on preventive healthcare, driven by an aging population. Miracell’s medical device systems are already in use globally in 36 countries, including the United States. These FDA- and KFDA-approved medical devices are widely used in operating rooms at hospitals and clinics. A platform has been developed to support hospitals and clinics nationwide, offering a safe system that is currently being tested with approximately 200 hospitals and clinics. CEO Shin Hyun-soon stated, “I hope Miracell’s program will be of some help to the public, who are hesitant due to the risk of infection caused by COVID-19.” Lee Soon-yong (sylee@edaily.co.kr)